Annovis Bio, Inc.
ANVSNYSEHealthcare● Active
$1.79
$-0.10(-5.29%)
Market Cap$35215771
P/E Ratio—
52W High$5.5
52W Low$1.54
Annovis Bio, Inc. (ANVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANVS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.63
Est. -$0.40 · -59.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS
ANVS reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.46 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.40 | -$0.63 | -59.5% | — | — | — |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.31 | -$0.39 | -26.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.36 | -$0.37 | -2.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.36 | -$0.32 | +11.1% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.47 | -$0.32 | +31.9% | — | — | — |
| ▼ Q1 FY2025 | Mar 21, 2025 | -$0.38 | -$0.43 | -13.2% | — | — | — |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.53 | -$0.97 | -83.0% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.63
EPS Est.
-$0.40
EPS Surpr.
-59.5%
Revenue
—
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.39
EPS Est.
-$0.31
EPS Surpr.
-26.5%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.37
EPS Est.
-$0.36
EPS Surpr.
-2.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.36
EPS Surpr.
+11.1%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.47
EPS Surpr.
+31.9%
Revenue
—
Q1 FY2025
Mar 21, 2025Miss
EPS Actual
-$0.43
EPS Est.
-$0.38
EPS Surpr.
-13.2%
Revenue
—
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$0.97
EPS Est.
-$0.53
EPS Surpr.
-83.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q1 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q3 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -59.5% | $2.13 | $2.06 | -3.29% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -26.5% | $2.52 | $2.83 | +12.30% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -2.8% | $2.11 | $2.43 | +15.17% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +11.1% | $2.82 | $2.77 | -1.77% |
| ▲ Q2 FY2025 | May 13, 2025 | +31.9% | $1.55 | $1.70 | +9.68% |
| ▼ Q1 FY2025 | Mar 21, 2025 | -13.2% | $1.80 | $1.75 | -2.78% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -83.0% | $8.61 | $8.16 | -5.23% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +30.2% | $7.96 | $7.76 | -2.51% |
Q2 FY2026-3.29%
Report Date
May 15, 2026
EPS Beat/Miss
-59.5%
Price Before
$2.13
Price After
$2.06
Q1 FY2026+12.30%
Report Date
Mar 16, 2026
EPS Beat/Miss
-26.5%
Price Before
$2.52
Price After
$2.83
Q4 FY2025+15.17%
Report Date
Nov 12, 2025
EPS Beat/Miss
-2.8%
Price Before
$2.11
Price After
$2.43
Q3 FY2025-1.77%
Report Date
Aug 12, 2025
EPS Beat/Miss
+11.1%
Price Before
$2.82
Price After
$2.77
Q2 FY2025+9.68%
Report Date
May 13, 2025
EPS Beat/Miss
+31.9%
Price Before
$1.55
Price After
$1.70
Q1 FY2025-2.78%
Report Date
Mar 21, 2025
EPS Beat/Miss
-13.2%
Price Before
$1.80
Price After
$1.75
Q4 FY2024-5.23%
Report Date
Nov 8, 2024
EPS Beat/Miss
-83.0%
Price Before
$8.61
Price After
$8.16
Q3 FY2024-2.51%
Report Date
Aug 14, 2024
EPS Beat/Miss
+30.2%
Price Before
$7.96
Price After
$7.76
Avg Beat Reaction+1.80%
Avg Miss Reaction+3.23%
Beat Rate3 / 8 quarters
Largest Move+15.17% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANVS ends December
Annovis Bio, Inc. (ANVS) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.63 — missing the analyst consensus of $-0.40 by -59.5%. The next ANVS earnings date is expected around September 1, 2026.
Each quarter, investors track ANVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANVS earnings · 5 questionsAnnovis Bio, Inc.'s next earnings report is expected around September 1, 2026. ANVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANVS historically reports after market close (AMC).
ANVS earnings datewhen is ANVS earningsANVS next earnings datewhen does ANVS report earningsANVS earnings calendar
▸ Source: FMP · Annovis Bio, Inc. SEC filings · US GAAP · Annovis Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026